Hims & Hers revenue accelerates 38% to $753.2 million

• Hims & Hers reported Q2 2026 revenue of $753.2 million, up 38% year over year, as subscribers reached nearly 2.9 million.
• Net loss reached $86.3 million and gross margin fell to 64% from 76%, while adjusted EBITDA declined to $60.3 million.
• Hims & Hers raised its 2026 revenue guidance to $3.1–$3.3 billion and expects adjusted EBITDA of $275–$325 million.

Hims & Hers Health (NYSE:HIMS) reported second-quarter 2026 revenue of $753.2 million, up 38% from $544.8 million a year earlier.

Gross margin fell to 64% from 76%, while Hims & Hers swung to an $86.3 million net loss from $42.5 million of net income.

“We have never been better positioned to move faster or go further than we are today,” said Hims & Hers co-founder and CEO Andrew Dudum.

Adjusted EBITDA declined to $60.3 million from $82.2 million, while free cash flow remained negative at $68.2 million.

Hims & Hers raised 2026 revenue guidance to $3.1–$3.3 billion; following the announcement the Hims & Hers share price was up about 0.6% at $31.77 in premarket trading.

Subscribers increased 19% to 2.89 million, while monthly revenue per average subscriber rose 21% to $92 and international revenue reached $131.4 million.

Hims & Hers completed its Eucalyptus acquisition in June and said international expansion, AI investments and broader personalized-care services remain part of its growth strategy.